Effect of non-steroidal anti-inflammatory drugs on bone turnover: An evidence-based review

Reviews on Recent Clinical Trials

Volumn 8, Issue 1, 2013, Pages 48-60

  Konstantinidis, Ioannis ^a   Papageorgiou, Spyridon N ^b   Kyrgidis, Athanassios ^c,d   Tzellos, Thrasivoulos George ^d   Kouvelas, Dimitrios ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Bone metabolism; Bone remodeling; Non steroidal anti inflammatory drug; Randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; AZAPROPAZONE; CELECOXIB; CODEINE PHOSPHATE; EXEMESTANE; FLURBIPROFEN; GLUCOSAMINE; IBUPROFEN; INDOMETACIN; LETROZOLE; MECLOFENAMATE SODIUM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PLACEBO;

ARTICLE; BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; DRUG EFFECT; DRUG EXPOSURE; EVIDENCE BASED MEDICINE; HUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; DISEASE PROGRESSION; HUMANS; HYDROXYPROLINE; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84874867318     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887111308010008     Document Type: Article

References (89)

1. Burd TA, Hughes MS, Anglen JO, Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 2003; 85: 700-5.
2. Sudmann E, Hagen T, Indomethacin-induced delayed fracture healing. Arch Orthop Unfallchir 1976; 85: 151-4.
3. Bo J, Sudmann E, Marton PF, Effect of indomethacin on fracture healing in rats. Acta Orthop Scand 1976; 47: 588-99.
4. O'Connor JP, Lysz T, Celecoxib, NSAIDs and the skeleton. Drugs Today (Barc) 2008; 44: 693-709.
5. Dodwell ER, Latorre JG, Parisini E, Zwettler E, Chandra D, Mulpuri K, et al., NSAID exposure and risk of nonunion: a metaanalysis of case-control and cohort studies. Calcif Tissue Int 2010; 87: 193-202.
6. Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, et al., Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 1996; 81: 3289-94.
7. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al., Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004; 19: 1250-8.
8. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C, Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12: 922-30.
9. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD, Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051-6.
10. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD, Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693-700.
11. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, et al., Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004; 34: 344-51.
12. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD, Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004; 19: 394-401.
13. Blake GM, Frost ML, Fogelman I, Quantitative radionuclide studies of bone. J Nucl Med 2009; 50: 1747-50.
14. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al., American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544-64.
15. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002; 9: 84-101.
16. Faulkner KG, Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000; 15: 183-7.
17. Hui SL, Slemenda CW, Johnston CC, Jr., Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989; 111: 355-61.
18. Marshall D, Johnell O, Wedel H, Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-9.
19. Bonnick SL, Shulman L, Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006; 119: S25-31.
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-34.
21. Higgins JPT, Green S, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 2011
22. Chow LW, Yip AY, Chu WP, Loo WT, Toi M, Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial. J Steroid Biochem Mol Biol 2011; 125: 112-9.
23. Jeffcoat MK, Williams RC, Reddy MS, English R, Goldhaber P, Flurbiprofen treatment of human periodontitis: effect on alveolar bone height and metabolism. J Periodontal Res 1988; 23: 381-5.
24. Kohrt WM, Barry DW, Van Pelt RE, Jankowski CM, Wolfe P, Schwartz RS, Timing of ibuprofen use and bone mineral density adaptations to exercise training. J Bone Miner Res 2010; 25: 1415-22.
25. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al., Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36: 279-87.
26. Lionberger DR, Noble PC, Celecoxib does not affect osteointegration of cementless total hip stems. J Arthroplasty 2005; 20: 115-22.
27. Manicourt DH, Bevilacqua M, Righini V, Famaey JP, Devogelaer JP, Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and-13 in patients with flare-up of osteoarthritis. Drugs R D 2005; 6: 261-71.
28. Petersen SG, Saxne T, Heinegard D, Hansen M, Holm L, Koskinen S, et al., Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training. Osteoarthritis Cartilage 2010; 18: 34-40.
29. Rai R, Cohen H, Dave M, Regan L, Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-7.
30. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
31. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, Contourenhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008; 61: 991-6.
32. Egger M, Davey Smith G, Schneider M, Minder C, Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
33. Harbord RM, Egger M, Sterne JA, A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006; 25: 3443-57.
34. Hozo SP, Djulbegovic B, Hozo I, Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
35. Dequeker J, Geusens P, Verstraeten A, Vanderschueren D, Nijs J, 1,25-Dihydroxyvitamin D3 stimulation test and the effect of a prostaglandin synthesis inhibitor (piroxicam) in young adults. Miner Electrolyte Metab 1991; 17: 353-6.
36. Gineyts E, Mo JA, Ko A, Henriksen DB, Curtis SP, Gertz BJ, et al., Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 2004; 63: 857-61.
37. Head JE, Bryant BJ, Grills BL, Ebeling PR, Effects of short-term use of ibuprofen or acetaminophen on bone resorption in healthy men: a double-blind, placebo-controlled pilot study. Bone 2001; 29: 437-41.
38. Adolphson P, Abbaszadegan H, Jonsson U, Dalen N, Sjoberg HE, Kalen S, No effects of piroxicam on osteopenia and recovery after Colles' fracture. A randomized, double-blind, placebo-controlled, prospective trial. Arch Orthop Trauma Surg 1993; 112: 127-30.
39. Alissa R, Sakka S, Oliver R, et al., Effect of ibuprofen of the bone cure in case of dental implants. A random clinical double blind, placebo-controlled study. Implantologie 2010; 18: 61-76.
40. Bichara J, Greenwell H, Drisko C, Wittwer JW, Vest TM, Yancey J, et al., The effect of postsurgical naproxen and a bioabsorbable membrane on osseous healing in intrabony defects. J Periodontol 1999; 70: 869-77.
41. Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F, Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; 2: 519-22.
42. Reddy MS, Palcanis KG, Barnett ML, Haigh S, Charles CH, Jeffcoat MK, Efficacy of meclofenamate sodium (Meclomen) in the treatment of rapidly progressive periodontitis. J Clin Periodontol 1993; 20: 635-40.
43. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al., Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756-65.
44. Salari P, Abdollahi M, Controversial effects of non-steroidal antiinflammatory drugs on bone: a review. Inflamm Allergy Drug Targets 2009; 8: 169-75.
45. Barry S, Non-steroidal anti-inflammatory drugs inhibit bone healing: a review. Vet Comp Orthop Traumatol 2010; 23: 385-92.
46. Fransen M, Neal B, Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 2004: CD001160.
47. Pountos I, Georgouli T, Calori GM, Giannoudis PV, Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. Scientific World Journal 2012; 2012: 606404.
48. Dimmen S, Nordsletten L, Engebretsen L, Steen H, Madsen JE, Negative effect of parecoxib on bone mineral during fracture healing in rats. Acta Orthop 2008; 79: 438-44.
49. Dimmen S, Nordsletten L, Madsen JE, Parecoxib and indomethacin delay early fracture healing: a study in rats. Clin Orthop Relat Res 2009; 467: 1992-9.
50. Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, et al., Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996; 11: 29-35.
51. Carbone LD, Tylavsky FA, Cauley JA, Harris TB, Lang TF, Bauer DC, et al., Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 2003; 18: 1795-802.
52. Ramamurthy NS, Rifkin BR, Greenwald RA, Xu JW, Liu Y, Turner G, et al., Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines. J Periodontol 2002; 73: 726-34.
53. Beck A, Krischak G, Sorg T, Augat P, Farker K, Merkel U, et al., Influence of diclofenac (group of nonsteroidal anti-inflammatory drugs) on fracture healing. Arch Orthop Trauma Surg 2003; 123: 327-32.
54. Brown KM, Saunders MM, Kirsch T, Donahue HJ, Reid JS, Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J Bone Joint Surg Am 2004; 86-A: 116-23.
55. Giordano V, Giordano M, Knackfuss IG, Apfel MI, Gomes RD, Effect of tenoxicam on fracture healing in rat tibiae. Injury 2003; 34: 85-94.
56. Goodman SB, Ma T, Mitsunaga L, Miyanishi K, Genovese MC, Smith RL, Temporal effects of a COX-2-selective NSAID on bone ingrowth. J Biomed Mater Res A 2005; 72: 279-87.
57. Hogevold HE, Grogaard B, Reikeras O, Effects of short-term treatment with corticosteroids and indomethacin on bone healing. A mechanical study of osteotomies in rats. Acta Orthop Scand 1992; 63: 607-11.
58. Leonelli SM, Goldberg BA, Safanda J, Bagwe MR, Sethuratnam S, King SJ, Effects of a cyclooxygenase-2 inhibitor (rofecoxib) on bone healing. Am J Orthop (Belle Mead NJ) 2006; 35: 79-84.
59. Murnaghan M, Li G, Marsh DR, Nonsteroidal anti-inflammatory drug-induced fracture nonunion: an inhibition of angiogenesis? J Bone Joint Surg Am 2006; 88 Suppl 3: 140-7.
60. Simon AM, Manigrasso MB, O'Connor JP, Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002; 17: 963-76.
61. Simon AM, O'Connor JP, Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J Bone Joint Surg Am 2007; 89: 500-11.
62. Spiro AS, Beil FT, Baranowsky A, Barvencik F, Schilling AF, Nguyen K, et al., BMP-7-induced ectopic bone formation and fracture healing is impaired by systemic NSAID application in C57BL/6-mice. J Orthop Res 2010; 28: 785-91.
63. Kasukawa Y, Miyakoshi N, Srivastava AK, Nozaka K, Maekawa S, Baylink DJ, et al., The selective cyclooxygenase-2 inhibitor celecoxib reduces bone resorption, but not bone formation, in ovariectomized mice in vivo. Tohoku J Exp Med 2007; 211: 275-83.
64. Lane N, Maeda H, Cullen DM, Kimmel DB, Cancellous bone behavior in hindlimb immobilized rats during and after naproxen treatment. Bone Miner 1994; 26: 43-59.
65. Jee WS, Li XJ, Li YL, Flurbiprofen-induced stimulation of periosteal bone formation and inhibition of bone resorption in older rats. Bone 1988; 9: 381-9.
66. Endo K, Sairyo K, Komatsubara S, Sasa T, Egawa H, Ogawa T, et al., Cyclooxygenase-2 inhibitor delays fracture healing in rats. Acta Orthop 2005; 76: 470-4.
67. Gerstenfeld LC, Al-Ghawas M, Alkhiary YM, Cullinane DM, Krall EA, Fitch JL, et al., Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment. J Bone Joint Surg Am 2007; 89: 114-25.
68. Krischak GD, Augat P, Blakytny R, Claes L, Kinzl L, Beck A, The non-steroidal anti-inflammatory drug diclofenac reduces appearance of osteoblasts in bone defect healing in rats. Arch Orthop Trauma Surg 2007; 127: 453-8.
69. Persson PE, Nilsson OS, Berggren AM, Do non-steroidal antiinflammatory drugs cause endoprosthetic loosening? A 10-year follow-up of a randomized trial on ibuprofen for prevention of heterotopic ossification after hip arthroplasty. Acta Orthop 2005; 76: 735-40.
70. Dahners LE, Mullis BH, Effects of nonsteroidal anti-inflammatory drugs on bone formation and soft-tissue healing. J Am Acad Orthop Surg 2004; 12: 139-43.
71. Gerstenfeld LC, Thiede M, Seibert K, Mielke C, Phippard D, Svagr B, et al., Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 2003; 21: 670-5.
72. Ho ML, Chang JK, Chuang LY, Hsu HK, Wang GJ, Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. Biochem Pharmacol 1999; 58: 983-90.
73. Igarashi K, Woo JT, Stern PH, Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro. Biochem Pharmacol 2002; 63: 523-32.
74. Jungkeit MC, Chole RA, Ibuprofen inhibits localized bone resorption in the middle ear. Calcif Tissue Int 1991; 48: 267-71.
75. Bell NH, Hollis BW, Shary JR, Eyre DR, Eastell R, Colwell A, et al., Diclofenac sodium inhibits bone resorption in postmenopausal women. Am J Med 1994; 96: 349-53.
76. Morton DJ, Barrett-Connor EL, Schneider DL, Nonsteroidal antiinflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. J Bone Miner Res 1998; 13: 1924-31.
77. Lane NE, Bauer DC, Nevitt MC, Pressman AR, Cummings SR, Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research Group. J Rheumatol 1997; 24: 1132-6.
78. Alvarez L, Guanabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, et al., Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995; 10: 458-65.
79. Stepan JJ, Silinkova-Malkova E, Havranek T, Formankova J, Zichova M, Lachmanova J, et al., Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 1983; 133: 189-200.
80. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP, The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991; 72: 382-6.
81. Stempfle HU, Birner H, Ellinger M, et al., Free pyridinoline crosslinks predict early bone loss after heart transplantation. J Bone Miner Res 1995; 10: T500.
82. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, et al., Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999; 5: 3914-9.
83. Bollen AM, Martin MD, Leroux BG, Eyre DR, Circadian variation in urinary excretion of bone collagen cross-links. J Bone Miner Res 1995; 10: 1885-90.
84. Christgau S, Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin Chem 2000; 46: 431.
85. Looker AC, Bauer DC, Chesnut CH, 3rd, Gundberg CM, Hochberg MC, Klee G, et al., Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000; 11: 467-80.
86. Schlemmer A, Hassager C, Jensen SB, Christiansen C, Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992; 74: 476-80.
87. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, et al., Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18: 2180-9.
88. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R, Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008; 42: 623-30.
89. Boivin G, Meunier PJ, Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact 2002; 2: 538-43.